Bausch + Lomb Corporation filings document the reporting obligations of a Canada-incorporated eye health company whose common shares trade on the New York Stock Exchange and Toronto Stock Exchange under BLCO. Its 8-K reports cover quarterly and annual operating results, non-GAAP financial measures, guidance, investor presentations, material credit-agreement amendments and refinancing activity.
Proxy materials describe annual shareholder meeting matters, board composition, director independence, committee assignments and executive compensation governance. Other event filings record board appointments, committee changes, registered common-share details and Regulation FD disclosures tied to the company's product pipeline, Pharmaceuticals, Surgical and Vision Care operations.
Bausch & Lomb Corp EVP and CFO Sam Eldessouky reported a tax-related share disposition. On May 5, 2026, 63,938 common shares were withheld at $16.00 per share to satisfy tax withholding obligations upon vesting of restricted share units. This was not an open-market sale. After this withholding, Eldessouky directly holds 343,192 common shares of Bausch & Lomb Corp.
Bausch & Lomb Corp executive Yehia Hashad, EVP of R&D and CMO, reported a routine tax-related share disposition on Form 4. On May 5, 2026, 13,664 common shares at $16.00 per share were withheld to cover tax obligations triggered by the vesting of restricted share units, rather than sold in the open market. After this withholding, Hashad directly holds 166,377 common shares, indicating he retains a substantial equity stake in the company.
Bausch & Lomb Corp senior vice president, controller and chief accounting officer Frederick Munsch reported a routine share disposition related to taxes. On May 5, 2026, 8,673 Common Shares at $16.00 per share were withheld to cover tax obligations upon vesting of restricted share units, rather than sold on the open market.
After this tax-withholding event, Munsch directly holds 89,640 Common Shares. The filing reflects a compensation-related withholding, not an open-market purchase or sale decision.
Bausch & Lomb Corp executive Luc Bonnefoy, President of Surgical, reported a routine tax-related share disposition. On the vesting of restricted share units, 11,970 common shares were withheld by the company to satisfy tax withholding obligations, rather than sold on the open market. Following this withholding, Bonnefoy directly holds 88,031 common shares, showing he retains a substantial equity position after the RSU vesting event.
ROBERTSON RUSSEL C reported acquisition or exercise transactions in this Form 4 filing.
Bausch & Lomb Corp director Russel C. Robertson received an equity award of 1,611 common shares on April 30, 2026. The filing describes these as restricted share units, each representing a contingent right to receive one common share of Bausch & Lomb.
After this grant, Robertson directly holds 78,418 common shares. This is a compensation-related grant, not an open-market purchase, and reflects additional alignment of the director’s interests with common shareholders through stock-based awards.
Bausch & Lomb Corp director John Paulson received an equity grant. He acquired 1,375 restricted share units, each representing a contingent right to receive one common share of Bausch & Lomb, at a reference price of $15.90 per share.
Following this grant, Paulson directly holds 73,981 common shares. This is a compensation-related award reported as an acquisition, not an open-market purchase or sale.
Bausch & Lomb Corp director Steven H. Collis received a grant of restricted share units in the company. On this award date, he acquired 1,415 restricted share units, each representing a contingent right to receive one common share of Bausch & Lomb. Following this award, his directly held common share-equivalent position reported in this filing is 26,161 shares.
Bausch & Lomb Corp director Alfonso Eduardo reported an acquisition of 1,375 common shares on April 30, 2026 through a grant of restricted share units. Each unit represents a contingent right to receive one common share at a reference price of $15.90 per share.
After this compensation-related award, Eduardo directly holds 15,230 common shares. This filing reflects an equity grant rather than an open-market purchase or sale, and does not involve any derivative exercises.
Bausch + Lomb Corporation reported first-quarter 2026 results showing higher sales but a continued net loss. Revenues reached $1,244 million, up from $1,137 million a year earlier, driven by product sales across its Vision Care, Pharmaceuticals and Surgical eye-health segments.
Operating income improved to $33 million from an operating loss of $83 million, and the net loss attributable to the company narrowed to $71 million from $212 million, or $0.20 per share versus $0.60. Cash from operating activities was $32 million compared with a $25 million use of cash in the prior-year quarter. As of March 31, 2026, total assets were $13,780 million, long-term debt and other financial liabilities (net of issuance costs) were about $5,039 million, and cash and cash equivalents were $268 million. Bausch Health Companies Inc. continued to own roughly 87% of Bausch + Lomb’s common shares, with 356,536,358 common shares outstanding as of April 22, 2026.
Bausch + Lomb reported solid first-quarter 2026 growth and raised its full-year outlook. Revenue reached $1.244 billion, up 9% from the first quarter of 2025, or 6% on a constant currency basis, driven by all three segments.
Vision Care revenue grew to $711 million, Surgical to $228 million, and Pharmaceuticals to $305 million, with Pharmaceuticals up 14% and led by strong MIEBO and XIIDRA sales. Operating results improved markedly, shifting from an operating loss of $83 million to operating income of $33 million.
The company still posted a GAAP net loss of $71 million, but adjusted net income was $19 million and cash flow from operations turned positive at $32 million. Adjusted EBITDA rose to $189 million, or $200 million excluding acquired IPR&D, prompting higher 2026 revenue and adjusted EBITDA guidance.